SCHEMBL5297530

SCHEMBL5297530

CCOc1ccccc1NCC(=O)O

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.62
GLA P06280 1/20 0.62
CYP2C19 P33261 1/20 0.61
GAA P10253 2/20 0.59
POLB P06746 1/20 0.55
KMT2A Q03164 6/20 0.55
KDM4E B2RXH2 1/20 0.54
TSHR P16473 2/20 0.54
EGFR P00533 1/20 0.54
LMNA P02545 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
MCL1 Q07820 1/20 0.51
THRB P10828 1/20 0.51
MEN1 O00255 2/20 0.51
HTT P42858 1/20 0.51
ALDH1A1 P00352 2/20 0.50
NPC1 O15118 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
P4HTM Q9NXG6 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10877174 0.87 GAA (0.59) L3MBTL1GLACYP2C19GAAPOLB
SCHEMBL5516797 0.86 L3MBTL1 (0.56) L3MBTL1GLACYP2C19POLBKMT2A
SCHEMBL19034905 0.86 TDP1 (0.61) L3MBTL1GLACYP2C19GAAPOLB
SCHEMBL3210116 0.84 CYP2C19 (0.67) L3MBTL1GLACYP2C19GAAPOLB
SCHEMBL9417499 0.83 PTPN1 (0.54) POLBKMT2ATSHRLMNATDP1
SCHEMBL1816768 0.83 POLB (0.56) GAAPOLBKMT2AKDM4ELMNA
SCHEMBL29557428 0.83 POLB (0.56) GAAPOLBKMT2AKDM4ELMNA
SCHEMBL5843850 0.82 BRD4 (0.63) L3MBTL1GAAKMT2AKDM4ELMNA
SCHEMBL1514578 0.81 POLB (0.72) L3MBTL1CYP2C19GAAPOLBKMT2A
SCHEMBL14273055 0.80 TDP1 (0.51) L3MBTL1GLAPOLBKDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-08-01 US disclosed
EP-3928836-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2021-12-29 EP disclosed
US-20070135499-A1 Hydrazide compounds AERIE PHARMACEUTICALS, INC. (US) 2007-06-14 US disclosed
WO-2007008942-A2 PHENYLAMINO-ACETIC ACID [1-(PYRIDIN-4-YL)-METHYLIDENE]-HYDRAZIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF G PROTEIN-COUPLED RECEPTOR KINASES FOR THE TREATMENT OF EYE DISEASES AERIE PHARMACEUTICALS, INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 L3MBTL1 4109/4885GLA 4233/4885CYP2C19 215/4885
US-20070135499-A1 Hydrazide compounds GRK4, GRK2, GRK1 L3MBTL1 4643/4885GLA 572/4885CYP2C19 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.